MiMedx Group (MiMedx Group) Interest Expense : $-6.3 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MiMedx Group's interest expense for the three months ended in Dec. 2023 was $ -1.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MiMedx Group's Operating Income for the three months ended in Dec. 2023 was $ 23.4 Mil. MiMedx Group's Interest Expense for the three months ended in Dec. 2023 was $ -1.6 Mil. MiMedx Group's Interest Coverage for the quarter that ended in Dec. 2023 was 14.71. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MiMedx Group Interest Expense Historical Data

The historical data trend for MiMedx Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Interest Expense Chart

MiMedx Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.71

-7.94

-4.98

-5.02

-6.46

MiMedx Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.45	-1.55	-1.52	-1.68	-1.59

MiMedx Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.3 Mil.

MiMedx Group (NAS:MDXG) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MiMedx Group's Interest Expense for the three months ended in Dec. 2023 was $-1.6 Mil. Its Operating Income for the three months ended in Dec. 2023 was $23.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $48.1 Mil.

MiMedx Group's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	23.426	/	-1.593
	=	14.71

The higher the ratio, the stronger the company's financial strength is.

MiMedx Group (MiMedx Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062

Website

https://www.mimedx.com

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Executives

Rice Doug	officer: Chief Financial Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper	officer: Chief Executive Officer	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein	officer: EVP, Research and Development	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson	officer: Chief Financial Officer	BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan	officer: Chief Accounting Officer	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv	officer: General Counsel	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow	officer: Chief Operating Officer	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap	officer: EVP & Chief Commercial Officer	8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves	officer: SVP & Chief Compliance Officer	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner	officer: SVP, Operations & Procurement	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani	director	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604